Shane Tillakeratne
Biographic Data
| ID | 7447558 |
|---|---|
| NAME | Shane Tillakeratne |
| GIVEN NAMES | Shane |
| FAMILY NAME | Tillakeratne |
| SIGNATURE | TILLAKERATNE S |
| AFFILIATIONS | UNSW Sydney |
| ORCID | 0000-0002-5988-3579 |
| VERIFIED | Yes |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program
Point-of-care HCV RNA testing, linkage to nursing, and peer-supported engagement/delivery led to high HCV treatment uptake (majority single-visit) among people with recent injecting drug use attending a peer-led NSP. The lower proportion of people with SVR highlights the need for further interventions to support treatment completion
No prominent works on this page.
Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program
Point-of-care HCV RNA testing, linkage to nursing, and peer-supported engagement/delivery led to high HCV treatment uptake (majority single-visit) among people with recent injecting drug use attending a peer-led NSP. The lower proportion of people with SVR highlights the need for further interventions to support treatment completion
Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use
The relatively high incidence of reinfection seen in this study underscores the importance of targeted harm reduction measures and monitoring for HCV reinfections within the first year following successful treatment among people who inject drugs. Additional research into integrated models of care incorporating harm reduction and supporting reducing risk of reinfection and HCV treatment are needed
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use
The high HCV reinfection incidence in prisons emphasises the need to enhance prison-based harm reduction measures including access to sterile injecting equipment, currently prohibited in Australian prisons. The finding that reinfection accounts for most recurrent viremia could assist retreatment clinical decision-making in prison
Hepatitis C virus research (5 works) · Hepatitis C (4 works) · Medicine (4 works) · Hepatitis C virus (3 works) · HIV, Drug Use, Sexual Risk (3 works) · Alcohol Consumption and Health Effects (2 works) · Antiviral therapy (2 works) · Demography (2 works) · Drug (2 works) · Hepatitis B Virus Studies (2 works)